Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Géczi, Lajos, Bodoky, György, Rokszin, György, Bajcsayné Fábián, Ibolya, Torday, László: Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
PATHOLOGY AND ONCOLOGY RESEARCH, 26 (4). pp. 2201-2207. ISSN 1219-4956 (2020)

[img]
Preview
Text
geczi-2020-sunitinib-NHIF.pdf - Published Version

Download (292kB) | Preview
Item Type: Article
Journal or Publication Title: PATHOLOGY AND ONCOLOGY RESEARCH
Date: 2020
Volume: 26
Number: 4
Page Range: pp. 2201-2207
ISSN: 1219-4956
Faculty: Faculty of Medicine
Institution: Szegedi Tudományegyetem
MTMT id: 31287337
DOI id: https://doi.org/10.1007/s12253-020-00809-z
Date Deposited: 2020. Oct. 13. 08:26
Last Modified: 2020. Oct. 13. 08:26
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/19706
Web of Science® Times Cited: 1 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year